Brief: Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
13/06/2024 12:38
June 13 (Reuters) - Pasithea Therapeutics Corp KTTA.O :
* PASITHEA THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT
AND
INITIAL DOSING OF COHORT 2 FOLLOWING POSITIVE SAFETY REVIEW
COMMITTEE (SRC) RECOMMENDATION FOR PAS-004 IN ONGOING PHASE 1
CLINICAL TRIAL
* PASITHEA THERAPEUTICS CORP: REMAIN ON TRACK TO PRESENT OUR
INITIAL SAFETY AND PHARMACOKINETIC (PK) DATA IN Q3 OF 2024.
Source text for Eikon: ID:nGNX9nhD2j
Further company coverage: KTTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement